Xellia Pharmaceuticals

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. Our anti-infective treatments are generics that combat serious bacterial and antibiotic resistant infections as well as certain fungal diseases. We are a world leader in the development, manufacturing and supply of fermented anti-infectives sold as active pharmaceutical ingredients and finished dosage forms to key pharmaceutical industry companies. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers. Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics sector. Xellia is the leading supplier of important anti-infectives vancomycin and colistimethate sodium (CMS). Our success and strong market position is built on more than 115 years experience in the pharmaceutical industry. Xellia Pharmaceuticals’ focus its R&D investments within injectable product technologies as we are committed to researching solutions, which not only improve patients’ quality of life, but will also save lives. Based on our long-term expertise, we bring value for our stakeholders and signify a patient-centric mindset through an embedded corporate motivation of integrating science and innovation to save lives.